Bimagrumab plus Semaglutid allein oder in Kombination zur Behandlung von Übergewicht oder Fettleibigkeit und Typ-2-Diabetes

The researchers in this study are testing the effects of new drugs for weight loss. The standard treatment for weight loss therapy is semaglutide, the active ingredient in wegovy and ozempic. The new add-on or independent therapy is bimagrumab, type II activin receptor antagonist, that can also cause weight loss through a different mechanism, than the mechanism of semaglutide, a GLP1 agonist.
They wanted to study the impact of each therapy on weight loss after 48 weeks. They had four groups of candidates for this study: a placebo, semaglutide only, bimagrumab only, and combined therapy. They found that the placebo group lost 7 lbs, semaglutide only group lost 31.3 lbs, bimagrumab only lost 20.5 lbs, and combined therapy group lost 39.2 lbs. All data is statistically significant.
The takeaway for me is that pharmacotherapy for weight loss treatment is a growing industry with many more drug candidates being studied. There are people who may have obesity or diabetes due to genetic factors who have tried lifestyle modifications, yet have not seen the results they wanted. This is valuable research that can help patients better manage their weight, and ultimately live a healthy and more fulfilling life.